I think your point goes to Item 6 on Mozz's list. However there only has to be evidence they can show safety and efficacy within the 6 years. The FDA are looking for support of claims and indications as well as relative benefits over existing treatments. That is a higher hurdle than efficacy IMO.
I think your point goes to Item 6 on Mozz's list. However...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 25.0¢ | $110.6K | 431.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 94172 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 30859 | 5 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |